Artiva Biotherapeutics, Inc. — Key Metrics
1 years of history · ending 2024-12-31 · SEC EDGAR
Forensics
Three classic accounting-quality scores. F-Score (0-9, higher = better fundamentals); M-Score (>-1.78 flags possible manipulation); Z-Score (>2.99 = safe, <1.81 = distressed). Use together — single-score readings are noisy.
F-Score (Piotroski 0-9)
Z-Score (Altman; <1.81 = distress)
Per Share Metrics
Expense Ratios
Working Capital Analysis
Valuation Multiples
Enterprise Value Multiples
52-Week Range
ROIC vs WACC
Yields
Capital Deployment Yields
EPS (Diluted)
$-6
Book Value Per Share
$17
Free Cash Flow Per Share
$-5
Cash Per Share
$4
Revenue Per Share
$0
OCF Per Share
$-5
Return on Equity
-530.9%
Return on Assets
-41.5%
Return on Invested Capital
-546.4%
Current Ratio
15.39
Quick Ratio
15.39
Asset Turnover
0.00
Days Sales Outstanding
0.00
R&D / Revenue
20051.0%
SBC / Revenue
2780.9%
Capex / Revenue
255.8%
Working Capital
$176M
Net Current Asset Value
$166M
Invested Capital
$187M
OCF / Net Income
0.84
FCF / Net Income
0.85
Accruals Ratio (Sloan)
-4.9%
Net Debt
$-185M
Net Debt / EBITDA
2.86
Capex Coverage
-85.72
Tangible Common Equity
$187M
TCE / Total Assets
89.1%
NOPAT
$-67M
Cash ROIC
-452.2%
WC / Revenue
70270.1%
Capex / D&A
0.26
Reinvestment Rate
2.7%
Asset Growth vs Revenue Growth
198.6%
Stock Price (FY-end)
$10
Market Cap
$113M
P/S Ratio
452.15
P/B Ratio
0.61
P/TB Ratio
0.61
Enterprise Value
$-72M
EV / Sales
-286.61
FCF Yield
-49.1%
Shareholder Yield
-6.2%
R&D Yield
44.3%
Capex Yield
0.6%
Shares Variation (YoY)
1302.5%
Beta (5Y)
1.45
Cost of Equity
11.8%
52W High
$16
52W Low
$10
Trailing Return 1Y
—
F-Score (Piotroski)
2.00
Z-Score (Altman)
1.27
Earnings Forecasts
Per-quarter consensus estimates + actuals + beat/miss surprise. Sourced from Finnhub (Wall Street consensus aggregation).
Source caveat: Finnhub free tier returns the consensus mean only — analyst high / low / dispersion + analyst counts require a paid plan. A "$5.00 consensus" line above could mean "20 analysts at exactly $5" (high conviction) or "10 at $5.50, 10 at $4.50" (split). Treat single-line consensus accordingly.